Researchers classify high-risk T-ALL into 15 subtypes using 60% non-coding genetic changes, potentially leading to new personalized treatments and immunotherapies.

Researchers from Children's Hospital of Philadelphia, St. Jude Children's Research Hospital, and the Children's Oncology Group, have revealed a significant shift in understanding high-risk T-lineage acute lymphoblastic leukemia (T-ALL) by studying over 1,300 patients. Approximately 60% of genetic changes driving T-ALL cancer cells are non-coding changes, fundamentally altering the understanding of T-ALL biology. The study allowed researchers to classify T-ALL into 15 subtypes with distinct gene expression and genomic drivers, which may lead to new personalized treatment plans and innovative immunotherapies.

August 14, 2024
7 Articles